AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 188 filers reported holding AKERO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,306,751 | +2.0% | 45,606 | -5.9% | 0.00% | 0.0% |
Q2 2023 | $2,262,177 | +61.5% | 48,451 | +32.3% | 0.00% | – |
Q1 2023 | $1,400,966 | +1307.0% | 36,617 | +1915.2% | 0.00% | – |
Q4 2022 | $99,571 | -93.4% | 1,817 | -95.9% | 0.00% | – |
Q3 2022 | $1,506,000 | +8758.8% | 44,235 | +2354.8% | 0.00% | – |
Q2 2022 | $17,000 | -70.7% | 1,802 | -55.9% | 0.00% | – |
Q1 2022 | $58,000 | -78.8% | 4,088 | -68.4% | 0.00% | – |
Q4 2021 | $274,000 | +2390.9% | 12,950 | +2614.9% | 0.00% | – |
Q3 2021 | $11,000 | +83.3% | 477 | +110.1% | 0.00% | – |
Q2 2021 | $6,000 | -45.5% | 227 | -39.8% | 0.00% | – |
Q1 2021 | $11,000 | -98.6% | 377 | -98.7% | 0.00% | – |
Q4 2020 | $774,000 | +294.9% | 30,022 | +369.6% | 0.00% | – |
Q3 2020 | $196,000 | -63.2% | 6,393 | -70.0% | 0.00% | – |
Q2 2020 | $532,000 | +309.2% | 21,334 | +247.2% | 0.00% | – |
Q1 2020 | $130,000 | +85.7% | 6,145 | +94.2% | 0.00% | – |
Q4 2019 | $70,000 | +677.8% | 3,164 | +719.7% | 0.00% | – |
Q3 2019 | $9,000 | – | 386 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |